Key Highlights

  • Shares are trading at $43.00 in pre-market activity, down 24.15% from Thursday's close of $57.35.
  • The company disclosed a voluntary pause in new patient enrollment for its azetukalner studies in major depressive disorder and bipolar depression following neuropsychiatric adverse events not previously seen in earlier trial phases.
  • The safety pause overshadowed a simultaneous positive milestone: the company submitted an NDA to the FDA for azetukalner in focal seizures, backed by strong Phase 2b/3 efficacy data.
  • Deutsche Bank downgraded the stock to Hold, cutting its price target to $46 from $90, while RBC maintained an Outperform/Speculative Risk rating but lowered its target to $70 from $81.

Enrollment Pause on Neuropsychiatric Signal Drives the Selloff

Xenon Pharmaceuticals (NASDAQ:XENE) shares plunged in pre-market trading Friday after the company disclosed a voluntary pause in new patient enrollment for its azetukalner (formerly XEN1101) studies in major depressive disorder and bipolar depression, following neuropsychiatric adverse events not previously seen in earlier trial phases. Xenon Pharmaceuticals is a Burnaby, British Columbia-based clinical-stage, neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for patients with neurological and psychiatric disorders.

Safety Signal Overshadows a Simultaneous Regulatory Milestone

The news overshadowed a simultaneous positive milestone, as the company also submitted a New Drug Application to the FDA for azetukalner in focal seizures, backed by strong Phase 2b/3 trial data. The safety signal, though described as consistent with the drug's known mechanism and expected to be temporary, has delayed topline data from the X-NOVA2 major depressive disorder study to the first quarter of 2027.

Analysts Split on How Much the Setback Should Weigh on the Stock

The reaction triggered a sharp analyst split: Deutsche Bank downgraded the stock to Hold and cut its price target to $46 from $90, while RBC maintained an Outperform/Speculative Risk rating even as it lowered its target to $70 from $81, reflecting a divide over how much the psychiatry-program setback should weigh against the epilepsy franchise's near-term approval potential.